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In 2015, the American College of Surgeons (ACoS) Commission on Cancer will require cancer centers to implement screening pro-
grams for psychosocial distress as a new criterion for accreditation. A joint task force from the American Psychosocial Oncology So-
ciety, the Association of Oncology Social Work, and the Oncology Nursing Society developed consensus-based recommendations to
guide the implementation of this requirement. In this review, the authors provide recommendations regarding each of the 6 compo-
nents necessary to meet the ACoS standard: 1) inclusion of psychosocial representation on the cancer committee, 2) timing of screen-
ing, 3) method=mode of screening, 4) tools for screening, 5) assessment and referral, and 6) documentation. Cancer 2014;120:2946-
54. VC 2014 American Cancer Society.
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INTRODUCTION
In 2015, the American College of Surgeons (ACoS) Commission on Cancer will require cancer centers to implement screen-
ing programs for psychosocial distress as a criterion for accreditation.1 Although the ACoS standard articulates the required
processes, cancer centers may benefit from guidance regarding the interpretation and customization of these requirements.
This review, which was written by a joint task force from the American Psychosocial Oncology Society (APOS), the Associa-
tion of Oncology Social Work (AOSW), and the Oncology Nursing Society (ONS), attempts to provide such guidance.
The APOS, AOSW, and ONS represent over 36,000 oncology social workers, psychologists, nurses, chaplains, psychiatrists,
and other physicians who provide psychosocial care to patients with cancer in the United States. The joint task force specifi-
cally developed consensus-based recommendations regarding the 6 components of the ACoS standard: 1) psychosocial repre-
sentation on the cancer committee with a committee meeting that includes plans for screening, 2) timing of screening, 3)
method=mode of screening, 4) tools for screening, 5) assessment and referral, and 6) documentation.
Screening for Psychosocial Distress
The National Comprehensive Cancer Network (NCCN) defines distress as an emotionally unpleasant psychological (cog-
nitive, behavioral, emotional), social, and=or spiritual experience that might interfere with a patient’s ability to effectively
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cope with cancer, its physical symptoms, and its treat-
ment.2 Psychosocial distress, a common yet treatable con-
dition in individuals with cancer, is associated with
suffering and worse outcomes.3-11 Data suggest that
screening for and addressing distress not only enhances
quality of life but also may be associated with improved
cancer outcomes.12-14 Unfortunately, distress often goes
unrecognized in oncology care, necessitating systematic
methods for its identification and treatment.15,16 Further-
more, psychosocial interventions can effectively reduce
distress created or exacerbated by cancer.17-22
In addition to the ACoS Commission on Cancer
standard, several other organizations, including the NCCN,
the Institute of Medicine, and the American Society of Clin-
ical Oncology, have identified the assessment and treatment
of psychosocial distress in routine cancer care as a quality
care standard.2,23,24 The NCCN has developed the Distress
Management Clinical Practice Guidelines, which outline
the steps for evaluating and addressing distress in the cancer
setting. The initial steps involve routine screening for psy-
chosocial distress and the development of a system of evalua-
tion and triage for those who screen positive, referral to
appropriate care if indicated, and follow-up to ensure
adequate care. These elements have been referred to as a
comprehensive distress screening process.25
Comprehensive Distress Screening Programs
Effective detection and treatment of distress in cancer set-
tings require a comprehensive distress screening program.
Such an approach involves not only the use of an appro-
priate distress screening instrument but also a system for
administering screening, reviewing screening results, con-
ducting follow-up assessments for patients identified as
distressed, and referring for further evaluation, support,
and treatment as needed. Moreover, the integration of a
distress screening program should be approached as rou-
tine in high-quality cancer care, reducing the stigma often
associated with mental health services.
The success of any comprehensive distress screening
program will depend on having sufficient and qualified
staff responsible for each component. The cancer care team
will require training in procedures for distress screening
and evaluation. Also, a network of psychosocial health care
providers must be identified to care for patients who screen
positive for distress and need further evaluation, support,
and treatment. Evidence suggests that screening alone, in
the absence of an established triage algorithm, does not
improve outcomes.26 This network may include in-house
mental health clinicians, especially at larger cancer care
facilities; community-based clinicians; and agencies that
can provide services. The network must also include an
interdisciplinary team of health care providers, such as
physicians, social workers, and nurses, to help address the
multifactorial causes of distress outside of mental health. In
addition, the delivery of psychosocial services by telephone
may be a cost-efficient adjunct for overcoming patient-level
and system-level barriers in accessing care.27-29
No single distress screening program will address the
specific needs of every cancer center or oncology practice
given variability in volume, resources, and culture. In the
section below, we identify considerations and provide rec-
ommendations regarding each of the 6 components of
ACoS standard 3.2, which will assist cancer centers in
designing their own comprehensive screening programs.
Six Components in the ACoS Standard
Thoughtful approaches to each of the 6 required compo-
nents will facilitate implementation of an effective, effi-
cient, clinically meaningful, safe, equitable, and
sustainable screening program. We believe that the rec-
ommendations below will assist cancer centers in achiev-
ing this goal, regardless of their setting, size, or resources.
1. Cancer committee meeting
The ACoS standard 3.2 requires documentation of dis-
cussion about screening for distress in the minutes of a
leadership committee meeting and that a psychosocial
representative (an “oncology social worker, clinical psy-
chologist, or other mental health professional trained in
the psychosocial aspects of cancer”) is identified to oversee
the administration of the program and report annually on
the program’s fidelity. The representative should be famil-
iar with rates and presentations of distress in cancer popu-
lations; basic clinical evaluation of distress; and the
existing resources available to the center for relevant evalu-
ations, treatment, and referrals. If no current staff member
possesses this knowledge, then the center should hire a
mental health professional with such expertise or provide
additional training for an appropriate psychosocial repre-
sentative before designing a screening program. Several
sources are available to obtain this training, including a
free online program offered by APOS (available at: www.
apos-society.org), a course offered by the ONS entitled
Integrating Psychosocial Care in Oncology Practice (available
at: http:==www2.ons.org=CourseDetail.aspx?course_id5
87), and the AOSW (www.aosw.org) (all Web sites
accessed April 22, 2014).
We recommend that the following information be
available to the cancer committee to guide the discussions
on screening: ACoS standard 3.2; volume of patients at
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the center (number of new patients per month, number of
daily ambulatory visits, etc); availability of mental health
clinicians within and outside the center; and the NCCN
guidelines for distress management. Given critical roles for
nursing and social work staff in the implementation of dis-
tress screening at many centers, nursing and social work
leadership should be involved in a collaborative effort.
We recommend that committee discussions begin
with the fifth component, evaluation and referral of dis-
tressed patients, which may require the most planning,
followed by the selection of a screening method. Commit-
tee discussions regarding the screening program should
address the development of clear procedures for screening
administration, scoring of responses, identification of
clinical thresholds, and implementation of an action plan
when patients exceed the clinical thresholds. Patient and
family advisory groups may be useful in providing feed-
back to committee members regarding acceptability of the
distress screening program for specific patient popula-
tions. Moreover, the distress screening program should be
integrated into the cancer center’s quality-assurance and
safety committees.
2. Timing of screening
The ACoS Committee on Cancer accreditation standard
requires that patients be screened at least once, at a
“pivotal medical visit.” The timing of screening should
occur at clinical visits when patients are at greatest risk for
distress (eg, at diagnosis, transitions in cancer treatment,
and completion of treatment).
TheNCCN Guidelines for Distress Management (ver-
sion 1.2013) also advise screening patients for distress at
their initial visit and at appropriate intervals thereafter as
clinically indicated, including at times of change in disease
status (such as remission, recurrence, and progression).2
These guidelines identify additional times of vulnerability
for distress, such as when patients undergo a diagnostic
workup, learn about a cancer diagnosis, terminate treat-
ment, etc (see Table 1).
Although no consensus on the exact timing of
screening for distress exists,30 the few examples from the
available research literature favor screening patients at ev-
ery visit.31,32 One article recommended screening at every
visit in medical oncology and weekly in radiation oncol-
ogy.33 In practice, however, most screening for psychoso-
cial distress occurs at entry into cancer care, which is
typically at the time of diagnosis.34 Other common time
points for screening include the start of a new treatment
modality, completion of treatment, or referral to palliative
care.35
To ensure universal assessment of patients, 1
approach would be to begin screening within a specific
time period after diagnosis. For example, screening for
distress by the second oncology visit would be consistent
with the ASCOQuality Oncology Practice Initiative mea-
sure.24 Delaying screening until after the initial visit may
limit the detection of temporary and transient anticipa-
tory distress related to diagnosis and facilitate more effi-
cient allocation of health care resources. Distress can
occur at various time points from a cancer diagnosis
onward and may go unrecognized if screening is con-
ducted only once.
3. Method=mode of screening
Multiple approaches are available to screen for distress
using either clinician-administered or patient-
administered assessments. Some screening assessments
can be completed with both methods.
One benefit of clinician-administered screening is
that it can be integrated into a review of systems evaluated
at every visit, permitting immediate scoring and interpre-
tation. Clinical intervention and triage can then occur in
real time, which is particularly important when assessing
acute risk (eg, suicidal ideation). Clinicians can immedi-
ately gauge whether a patient accurately comprehends a
screening item and, if necessary, clarify responses. How-
ever, clinician-administered screening is time-intensive,
and some patients may be more frank using self-
administered forms.36 Also, nonmental health professio-
nals may have limited training in how to ask and respond
to questions regarding psychosocial distress.
Alternatively, patient-administered screening can
consist of paper-and-pencil or electronic questionnaires
with automatic scoring. Patients can complete such ques-
tionnaires in the clinic waiting room, during
TABLE 1. Periods of Increased Vulnerability for Dis-
tress Among Patients With Cancera
Period
Finding a suspicious symptom
During diagnostic workup
Finding out the diagnosis
Awaiting treatment
Change in treatment modality
End of treatment
Discharge from hospital following treatment
Transition to survivorship
Medical follow-up and surveillance
Treatment failure
Recurrence/progression
Advanced cancer
End of life
a See National Comprehensive Cancer Network 2013.2
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chemotherapy infusion, or before medical visits. This
method affords greater privacy than face-to-face assess-
ment, facilitating disclosure of distress and other sensitive
concerns. However, the approach requires scoring of
patient responses and clinician review, which must occur
immediately to address any responses indicating severe
distress or risk concerns (eg, suicidal ideation). Finally,
the validity of patient-administered questionnaires may
be compromised by factors such as visual impairments,
low literacy or language barriers, difficulty comprehend-
ing certain items, and family members completing ques-
tionnaires on behalf of the patient.
Electronic administration of distress screening, which
can provide immediate scoring, has become increasingly
available and affordable. Some electronic systems may facili-
tate immediate triage, providing patients with referral infor-
mation and educational materials.37-39 Assessment tools
that integrate with the electronic health record can populate
the medical record with patient-reported data while also
tracking distress over time. This approach requires the avail-
ability of portable electronic devices, computer kiosks in
clinic, or remote internet access for patients.
If patients are able to complete questionnaires remotely
by mail or online, processes should be in place to attend to
their responses quickly, particularly if they indicate that they
are in severe distress or in danger of self-harm. To limit liabil-
ity, a conservative approach would be to refrain from asking
questions about potential for self-harm or other-harm unless
the questionnaire is administered in the clinic. However, this
approach may severely limit the utility of the screening mea-
sure and limit the information obtained.
4. Screening tools
Oncology clinicians often fail to recognize patient distress
in clinical encounters,40 underscoring the need for stand-
ardized screening methods. Ideally, each patient would
meet with a clinician for a comprehensive psychosocial
assessment at key time points during routine cancer care.
However, because this approach is not practical in most
settings, cancer centers should screen patients using brief,
well validated screening tools.
Because distress has multiple dimensions, tools that
assess only 1 aspect, such as depression or anxiety, are not
sufficient. In addition, distress can occur in relation to
other symptoms or quality-of-life issues, such as physical
symptoms (ie, nausea or fatigue) or social concerns (ie, fi-
nancial burden or family changes), and multidimensional
screening may be indicated to understand the distress.
Various tools exist to screen for distress. These have
been reviewed in detail elsewhere.34,41-43 These tools vary
in length, comprehensiveness, cultural equivalence, and
sensitivity=specificity for identifying patients who need
further evaluation. Although not exhaustive, Table 2
includes some examples of instruments that have been
validated with meaningful threshold values and applic-
ability to individuals with cancer. We recommend select-
ing an instrument that has been psychometrically
validated, preferably in patients with cancer. Considera-
tion should be given to the availability of the instrument
in other languages and its performance across diverse cul-
tures and ethnic groups. Research is ongoing to develop
and test an expanding array of screening options.
Documentation of a provider’s judgment that a patient
is “coping adequately” does not fulfill the ACoS require-
ments if a standardized method for screening was not used.
Moreover, we assert that more than 1 domain of distress
must be assessed to meet the requirement. Examples of mini-
mally acceptable instruments are the Distress Thermometer
and the Patient Health Questionnaire-4 (PHQ-4).
Care providers should select a tool with considera-
tion of patient burden, completion time, and ease of scor-
ing. Deleting items from well established tools to make
them briefer is unacceptable unless a validated shorter ver-
sion exists. The sensitivity and specificity of instruments
may inform an institution’s selection of a screening tool,
especially when considering available resources for follow-
up care should a patient screen positive for distress. How-
ever, we recommend that the results of validated screening
instruments should be interpreted using the published
threshold values rather than modifying the cutoff scores to
limit the volume of indicated follow-up assessments or
mental health referrals.
5. Evaluation and referral
Because the goal of screening for psychosocial distress is to
identify patients who need further assessment, support,
and intervention, centers should implement screening
only after developing a plan for reviewing results and
managing patients whose scores suggest clinically signifi-
cant distress. Research indicates that screening for distress
improves patient outcomes only when linked to an effec-
tive system of treatment.56,57 Therefore, a process for eval-
uation and appropriate referral is the central component
of a screening program.
We recommend developing a standardized protocol
for scoring and reviewing the results of screening: identify-
ing patients who require a follow-up assessment, conduct-
ing follow-up assessments, and referring for further
evaluation if indicated. These steps should be carried out
in a timely manner to address significant distress and
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safety concerns. The protocol should contain the follow-
ing personnel roles: 1) a staff member responsible for
overseeing the administration of the screening tool, col-
lecting the screening results, and ensuring that a qualified
clinician reviews the data; 2) a clinician or team of clini-
cians (nurse, social worker, psychologist, or physician) re-
sponsible for reviewing the screening data, determining
which patients require a follow-up assessment based on
the established criteria of the screening instrument, and
ensuring those patients receive follow-up assessment; and
3) a clinician or team of clinicians (nurse, social worker,
psychologist, or physician) responsible for the subsequent
follow-up assessment of distressed patients.
Examples of protocols are these: A medical assistant
could oversee the collection of screening data, which a nurse
then reviews. The nurse identifies patients who meet criteria
for a follow-up assessment and notifies a social worker who
could conduct the follow-up assessment and determine
whether further evaluation or referral is necessary. Alterna-
tively, an oncologist could be responsible for all of the
above elements—administering a screening instrument,
reviewing the results, and then referring the patient for fur-
ther evaluation or to appropriate services as needed. Some
electronic screening packages automate the referral func-
tion, streamlining the process for a busy setting.
The goal of follow-up assessment for patients who
meet the established criteria for distress is to clarify the na-
ture of the distress and determine whether further action
is needed. A follow-up assessment should include review-
ing the results of the screening instrument, obtaining a
brief history, and possibly administering additional assess-
ment instruments to clarify the type, severity, and sources
of distress. Any preliminary diagnoses or clarifications
should be documented in the patient’s medical record. In
addition, we recommend that the clinician ask about sui-
cidal ideation, given the increased risk of suicide in indi-
viduals with cancer.58 If nonmental health clinicians
identify suicidal ideation, then we recommend an imme-
diate mental health evaluation to assess risk and determine
the appropriate level of care.
When a potential psychosocial problem is identified,
a referral for further focused evaluation and treatment is
usually warranted. In these patients, the NCCN guide-
lines regarding distress management should be followed.
Also, nonclinicians, such as patient navigators or finance
staff, are often equipped to address barriers to care, such as
transportation problems or need for financial assistance.
The specific strategies that each cancer center
employs to ensure adequate treatment for distressed
patients will vary according to the center’s specific patient
population and available resources. However, we recom-
mend an integrated care system that provides population-
based, patient-centered psychosocial care that tracks out-
comes and overcomes organizational challenges to care.
For example, the evidence-based principles of stepped col-
laborative care represent such a system.59
6. Documentation
The clinician should document in the medical record the
instrument used, results, and clinical interpretation of
screening. Electronic importing of computerized screens,
scanning of completed pen-and-paper instruments, and
recording a patient’s score within a clinical note are ac-
ceptable methods. For patients in whom distress is identi-
fied, a clinician should document the following at the
appropriate time points: the review of screening results;
plan for follow-up assessment; type, source, and severity
of the distress; relevant history; any suicidal ideation; and
types of recommended interventions, including a plan for
further evaluation and by whom, or that no further evalu-
ation or treatment is needed.
If a patient declines any of the aforementioned steps,
then the clinician should document the patient refusal
with the stated reasons. A patient may not have the right
to refuse further evaluation if a safety risk is identified,
and timely documentation is of vital clinical and medical-
legal importance in such patients.60
Conclusions
The implementation of programs to screen for psychosocial
distress will enhance the quality of cancer care in institu-
tions that comply with the ACoS standard for psychosocial
distress screening. If cancer centers develop programs strate-
gically and systematically, then screening can be imple-
mented in a cost-efficient and sustainable way. Our hope is
that oncology care institutions will seize this opportunity to
provide personalized psychosocial care that could lead to
decreased suffering, enhanced satisfaction with care, and,
ultimately, improved health outcomes.
FUNDING SUPPORT
No specific funding was disclosed.
CONFLICT OF INTEREST DISCLOSURES
Dr. Deshields reports Speakers’ Bureau fees from Lilly Oncology.
REFERENCES
1. American College of Surgeons Committee on Cancer. Cancer Pro-
gram Standards 2012 Version 1.1: Ensuring Patient-Centered Care.
Chicago, IL: American College of Surgeons; 2012.
2. National Comprehensive Cancer Network (NCCN). NCCN Clini-
cal Practice Guidelines in Oncology: Distress Management. Version
Review Article
2952 Cancer October 1, 2014
3.2013. Fort Washington, PA: National Comprehensive Cancer Net-
work; 2013. Available at: https:==www.nccn.org=. Accessed Decem-
ber 17, 2013.
3. Hoffman B, Zevon M, D’Arrigo M, Cecchini T. Screening for dis-
tress in cancer patients: the NCCN rapid-screening measure. Psy-
chooncology. 2004;13:792-799.
4. Jacobsen PB, Donovan KA, Trask PC, et al. Screening for psycho-
logic distress in ambulatory cancer patients. Cancer. 2005;103:1494-
1502.
5. Trask PC, Paterson A, Riba M, et al. Assessment of psychological
distress in prospective bone marrow transplant patients. Bone Mar-
row Transplant. 2002;29:917-925.
6. Kennard BD, Stewart SM, Olvera R, et al. Nonadherence in adoles-
cent oncology patients: preliminary data on psychological risk factors
and relationships to outcome. J Clin Psychol Med Settings. 2004;11:
31-39.
7. Von Essen L, Larsson G, Oberg K, Sjoden PO. “Satisfaction with
care”: associations with health-related quality of life and psychosocial
function among Swedish patients with endocrine gastrointestinal
tumours. Eur J Cancer Care (Engl). 2002;11:91-99.
8. Skarstein J, Aass N, Fossa SD, Skovlund E, Dahl AA. Anxiety and
depression in cancer patients: relation between the Hospital Anxiety
and Depression Scale and the European Organization for Research
and Treatment of Cancer Core Quality of Life Questionnaire. J Psy-
chosom Res. 2000;49:27-34.
9. Greer J, Pirl W, Park E, Lynch T, Temel J. Behavioral and psycho-
logical predictors of chemotherapy adherence in patients with
advanced non-small cell lung cancer. J Psychosom Res. 2008;65:549-
552.
10. Pirl W, Greer J, Traeger L, et al. Depression and survival in meta-
static non-small-cell lung cancer: effects of early palliative care. J
Clin Oncol. 2012;30:1310-1315.
11. Zabora J, BrintzenhofeSzoc K, Jacobsen P, et al. A new psychosocial
screening instrument for use with cancer patients. Psychosomatics.
2001;42:241-246.
12. Andersen B, Thornton L, Shapiro C, et al. Biobehavioral, immune,
and health benefits following recurrence for psychological interven-
tion participants. Clin Cancer Res. 2010;16:3270-3278.
13. Giese Davis J, Collie K, Rancourt KMS, Neri E, Kraemer H,
Spiegel D. Decrease in depression symptoms is associated with lon-
ger survival in patients with metastatic breast cancer: a secondary
analysis. J Clin Oncol. 2011;29:413-420.
14. Pirl WF, Greer JA, Gallagher ER, Temel JS, Traeger L, Lennes IT.
Association of screening for psychosocial distress in patients with
newly diagnosed stage IV NSCLC and survival [abstract]. J Clin
Oncol. 2012;30(15S). Abstract 9030.
15. Carlson LE, Angen M, Cullum J, et al. High levels of untreated dis-
tress and fatigue in cancer patients. Br J Cancer. 2004;90:2297-
2304.
16. Passik SD, Dugan W, McDonald MV, Rosenfeld B, Theobald DE,
Edgerton S. Oncologists’ recognition of depression in their patients
with cancer. J Clin Oncol. 1998;16:1594-1600.
17. Meyer TJ, Mark MM. Effects of psychosocial interventions with
adult cancer patients: a meta-analysis of randomized experiments.
Health Psychol. 1995;14:101-108.
18. Trijsburg RW, van Knippenberg FC, Rijpma SE. Effects of psycho-
logical treatment on cancer patients: a critical review. Psychosom
Med. 1992;54:489-517.
19. Cwikel JG, Behar L, Rabson-Hare J. A comparison of a vote count
and a meta-analysis review of intervention research with adult cancer
patients. Res Soc Work Pract. 2000;10:139-158.
20. Gottlieb B, Wachala E. Cancer support groups: a critical review of
empirical studies. Psychooncology. 2007;16:379-400.
21. Jacobsen PB, Jim HS. Psychosocial interventions for anxiety and
depression in adult cancer patients: achievements and challenges. CA
Cancer J Clin. 2008;58:214-230.
22. Graves K. Social cognitive theory and cancer patients’ quality of life:
a meta-analysis of psychosocial intervention components. Health Psy-
chol. 2003;22:210-219.
23. Adler NE, Page A, eds; Institute of Medicine Committee on Psycho-
social Services to Cancer Patients=Families in a Community Setting.
Cancer Care for the Whole Patient. Washington, DC: National Aca-
demies Press; 2008.
24. American Society of Clinical Oncology. QOPI: The Quality Oncol-
ogy Practice Initiative. Available at: http:==qopi.asco.org=. Accessed
December 17, 2013.
25. Lazenby M, Dixon J, Bai M, McCorkle R. Comparing the distress
thermometer (DT) with the patient health questionnaire (PHQ)-2
for screening for possible cases of depression among patients newly
diagnosed with advanced cancer. Palliat Support Care. 2014;12:63-
68.
26. Hollingworth W, Metcalfe C, Mancero S, et al. Are needs assess-
ments cost effective in reducing distress among patients with cancer?
A randomized controlled trial using the Distress Thermometer and
Problem List. J Clin Oncol. 2013;31:3631-3638.
27. Marcus A, Garrett K, Cella D, et al. Can telephone counseling post-
treatment improve psychosocial outcomes among early stage breast
cancer survivors? Psychooncology. 2010;19:923-932.
28. DuHamel K, Mosher C, Winkel G, et al. Randomized clinical trial
of telephone-administered cognitive-behavioral therapy to reduce
post-traumatic stress disorder and distress symptoms after hemato-
poietic stem-cell transplantation. J Clin Oncol. 2010;28:3754-3761.
29. Kroenke K, Theobald D, Wu J, et al. Effect of telecare management
on pain and depression in patients with cancer: a randomized trial.
JAMA. 2010;304:163-171.
30. Thomas B, Nandamohan V, Nair M, Robinson J, Pandey M.
Screening for distress (the sixth vital sign) in a global recession: sus-
tainable approach to maintain patient-centered care. Future Oncol.
2009;5:727-738.
31. Shimizu K, Ishibashi Y, Umezawa S, et al. Feasibility and usefulness
of the “Distress Screening Program in Ambulatory Care” in clinical
oncology practice. Psychooncology. 2010;19:718-725.
32. Vitek L, Rosenzweig M, Stollings S. Distress in patients with cancer:
definition, assessment, and suggested interventions. Clin J Oncol
Nurs. 2007;11:413-418.
33. Kendall J, Glaze K, Oakland S, Hansen J, Parry C. What do 1281
distress screeners tell us about cancer patients in a community cancer
center? Psychooncology. 2011;20:594-600.
34. Carlson L, Waller A, Mitchell A. Screening for distress and unmet
needs in patients with cancer: review and recommendations. J Clin
Oncol. 2012;30:1160-1177.
35. Carlson L, Bultz B. Cancer distress screening. Needs, models, and
methods. J Psychosom Res. 2003;55:403-409.
36. Dupont A, Wheeler J, Herndon J, et al. Use of tablet personal com-
puters for sensitive patient-reported information. J Support Oncol.
2009;7:91-97.
37. Abernethy A, Ahmad A, Zafar SY, Wheeler J, Reese J, Lyerly HK.
Electronic patient-reported data capture as a foundation of rapid
learning cancer care. Med Care. 2010;48(6 suppl):S32-S38.
38. Clark K, Bardwell WA, Arsenault T, DeTeresa R, Loscalzo M.
Implementing touch-screen technology to enhance recognition of
distress. Psychooncology. 2009;18:822-830.
39. Miller M, Buzaglo J, Clark K, et al. Demonstrating the psychomet-
ric properties of a problem-related distress screener in a community
sample of 319 cancer survivors. Psychooncology. 2013;22:1249-1257.
40. Werner A, Stenner C, Schuz J. Patient versus clinician symptom
reporting: how accurate is the detection of distress in the oncologic
after-care? Psychooncology. 2012;21:818-826.
41. Kayser K, Acquati C, Tran T. No patients left behind: a systematic
review of the cultural equivalence of distress screening instruments. J
Psychosoc Oncol. 2012;30:679-693.
42. Vodermaier A, Linden W, Siu C. Screening for emotional distress in
cancer patients: a systematic review of assessment instruments. J Natl
Cancer Inst. 2009;101:1464-1488.
43. Luckett T, Butow P, King M, et al. A review and recommendations
for optimal outcome measures of anxiety, depression and general dis-
tress in studies evaluating psychosocial interventions for English-
speaking adults with heterogeneous cancer diagnoses. Support Care
Cancer. 2010;18:1241-1262.
44. Mitchell A. Pooled results from 38 analyses of the accuracy of dis-
tress thermometer and other ultra-short methods of detecting cancer-
related mood disorders. J Clin Oncol. 2007;25:4670-4681.
Distress Screening Recommendations/Pirl et al
Cancer October 1, 2014 2953
45. Thekkumpurath P, Walker J, Butcher I, et al. Screening for major
depression in cancer outpatients: the diagnostic accuracy of the 9-
item patient health questionnaire. Cancer. 2011;117:218-227.
46. Ryan D, Gallagher P, Wright S, Cassidy E. Sensitivity and specific-
ity of the Distress Thermometer and a 2-item depression screen
(Patient Health Questionnaire-2) with a “help” question for psycho-
logical distress and psychiatric morbidity in patients with advanced
cancer. Psychooncology. 2012;21:1275-1284.
47. Fann J, Berry D, Wolpin S, et al. Depression screening using the
Patient Health Questionnaire-9 administered on a touch screen com-
puter. Psychooncology. 2009;18:14-22.
48. Reuter K, Harter M. Screening for mental disorders in cancer
patients—discriminant validity of HADS and GHQ-12 assessed by
standardized clinical interview. Int J Methods Psychiatr Res. 2001;10:
86-96.
49. Goldberg DWilliams P. A User’s Guide to the General Health
Questionnaire (GHQ). Windsor, United Kingdom: NFER-Nelson;
1988.
50. Morasso G, Costantini M, Viterbori P, et al. Predicting mood disor-
ders in breast cancer patients. Eur J Cancer. 2001;37:216-223.
51. Morasso G, Costantini M, Baracco G, Borreani C, Capelli M.
Assessing psychological distress in cancer patients: validation of a
self-administered questionnaire. Oncology. 1996;53:295-302.
52. Mitchell A, Meader N, Symonds P. Diagnostic validity of the Hos-
pital Anxiety and Depression Scale (HADS) in cancer and palliative
settings: a meta-analysis. J Affect Disord. 2010;126:335-348.
53. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression
Scale. Acta Psychiatr Scand. 1983;67:361-370.
54. Thekkumpurath P, Venkateswaran C, Kumar M, Newsham A,
Bennett M. Screening for psychological distress in palliative care:
performance of touch screen questionnaires compared with semi-
structured psychiatric interview. J Pain Sympt Manage. 2009;38:597-
605.
55. Recklitis C, Rodriguez P. Screening childhood cancer survivors with
the Brief Symptom Inventory-18: classification agreement with the
symptom checklist-90-revised. Psychooncology. 2007;16:429-436.
56. Carlson L, Groff S, Maciejewski O, Bultz B. Screening for distress
in lung and breast cancer outpatients: a randomized controlled trial.
J Clin Oncol. 2010;28:4884-4891.
57. Gilbody S, Bower P, Fletcher J, Richards D, Sutton A. Collaborative
care for depression: a cumulative meta-analysis and review of longer-
term outcomes. Arch Intern Med. 2006;166:2314-2321.
58. Misono S, Weiss N, Fann J, Redman M, Yueh B. Incidence of sui-
cide in persons with cancer. J Clin Oncol. 2008;26:4731-4738.
59. Fann J, Ell K, Sharpe M. Integrating psychosocial care into cancer
services. J Clin Oncol. 2012;30:1178-1186.
60. Jacobs D. A Resource Guide for Implementing the Joint Commis-
sion on Accreditation of Healthcare Organizations (JCAHO) 2007
Patient Safety Goals on Suicide. Wellesley Hills, MA: American
Hospital Association; 2007: Available at: http:==www.aha.
org=content=00-10=JCAHOSafetyGoals2007.pdf. Accessed Decem-
ber 17, 2013.
Review Article
2954 Cancer October 1, 2014
